Verzenio
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Verzenio
- Generic name
- ABEMACICLIB
- Manufacturer
- Eli Lilly and Company
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- be4bc0de-0fdc-4d46-8d25-be43c79e6a06
- SPL ID
- 02db1b7f-c6fc-4f7c-96d3-8ab9b8b97068
- Version
- 31
- Effective date
- 2026-09-18
- Source export date
- 2026-11-13
- Source partition
- 3
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2df682709a18af7b632162dce4573ac151d74d432118e70b8675083d83b89813/drug-label-0003-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:47:23
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 208716 | derived:openfda.application_number |
| application number | NDA208716 | openfda.application_number | |
| brand name | Verzenio | openfda.brand_name | |
| generic name | ABEMACICLIB | openfda.generic_name | |
| manufacturer name | Eli Lilly and Company | openfda.manufacturer_name | |
| ndc | package | 0002-5337-63 | openfda.package_ndc |
| ndc | package | 0002-5337-62 | openfda.package_ndc |
| ndc | package | 0002-4483-54 | openfda.package_ndc |
| ndc | package | 0002-4815-54 | openfda.package_ndc |
| ndc | package | 0002-5337-54 | openfda.package_ndc |
| ndc | package | 0002-6216-54 | openfda.package_ndc |
| ndc | package | 0002-4483-62 | openfda.package_ndc |
| ndc | package | 0002-4815-62 | openfda.package_ndc |
| ndc | product | 0002-5337 | openfda.product_ndc |
| ndc | product | 0002-4483 | openfda.product_ndc |
| ndc | product | 0002-4815 | openfda.product_ndc |
| ndc | product | 0002-6216 | openfda.product_ndc |
| ndc11 | package | 00002533754 | derived:openfda.package_ndc |
| ndc11 | package | 00002448354 | derived:openfda.package_ndc |
| ndc11 | package | 00002481562 | derived:openfda.package_ndc |
| ndc11 | package | 00002481554 | derived:openfda.package_ndc |
| ndc11 | package | 00002621654 | derived:openfda.package_ndc |
| ndc11 | package | 00002533762 | derived:openfda.package_ndc |
| ndc11 | package | 00002448362 | derived:openfda.package_ndc |
| ndc11 | package | 00002533763 | derived:openfda.package_ndc |
| rxcui | 1946838 | openfda.rxcui | |
| rxcui | 1946844 | openfda.rxcui | |
| rxcui | 1946836 | openfda.rxcui | |
| rxcui | 1946842 | openfda.rxcui | |
| rxcui | 1946830 | openfda.rxcui | |
| rxcui | 1946848 | openfda.rxcui | |
| rxcui | 1946840 | openfda.rxcui | |
| rxcui | 1946846 | openfda.rxcui | |
| spl id | 02db1b7f-c6fc-4f7c-96d3-8ab9b8b97068 | id | |
| spl set id | be4bc0de-0fdc-4d46-8d25-be43c79e6a06 | set_id | |
| unii | 60UAB198HK | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Diarrhea: VERZENIO can cause severe cases of diarrhea, associated with dehydration and infection. Instruct patients at the first sign of loose stools to initiate antidiarrheal therapy, increase oral fluids, and notify their healthcare provider. ( 2.2 , 5.1 ) Neutropenia: Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. ( 2.2 , 5.2 ) Interstitial Lung Disease (ILD)/Pneumonitis: Severe and fatal cases of ILD/pneumonitis have been reported. Monitor for clinical symptoms or radiological changes indicative of ILD/pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis. ( 2.2 , 5.3 ) Hepatotoxicity: Increases in serum transaminase levels have been observed. Perform liver function tests (LFTs) before initiating treatment with VERZENIO. Monitor LFTs every two weeks for the first two months, monthly for the next 2 months, and as clinically indicated. ( 2.2 , 5.4 ) Venous Thromboembolism: Monitor patients for signs and symptoms of thrombosis and pulmonary embolism and treat as medically appropriate. ( 2.2 , 5.5 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ( 5.6 , 8.1 , 8.3 ) Increased Serum Creatinine Without Affecting Renal Function: Increases in serum creatinine can occur. Use alternative measures that are not based on serum creatinine to assess renal function. ( 5.7 ) 5.1 Diarrhea Severe diarrhea associated with dehydration and infection occurred in patients treated with VERZENIO. Across five clinical trials in 3899 patients, diarrhea occurred in 81% to 90% of patients who received VERZENIO. Grade 3 diarrhea occurred in 8% to 20% of patients receiving VERZENIO [see Adverse Reactions ( 6.1 )]. Most patients experienced diarrhea during the first month of VERZENIO treatment. The median time to onset of the first diarrhea event ranged from 6 to 8 days; and the median duration of Grade 2 and Grade 3 diarrhea ranged from 6 to 11 days and 5 to 8 days, respectively. Across trials, 19% to 26% of patients with diarrhea required a VERZENIO dose interruption and 13% to 23% required a dose reduction. Instruct patients to start antidiarrheal therapy such as loperamide at the first sign of loose stools, increase oral fluids, and notify their healthcare provider for further instructions and appropriate follow up [see Patient Counseling Information ( 17 )]. For Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization, withhold VERZENIO until resolution to ≤Grade 1, and then resume VERZENIO at the next lower dose [see Dosage and Administration ( 2.2 )] . 5.2 Neutropenia Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with VERZENIO. Across five clinical trials in 3899 patients, neutropenia occurred in 37% to 51% of patients receiving VERZENIO. A Grade ≥3 decrease in neutrophil count (based on laboratory findings) occurred in 19% to 32% of patients receiving VERZENIO. Across trials, the median time to the first episode of Grade ≥3 neutropenia ranged from 29 days to 34 days, and the median duration of Grade ≥3 neutropenia ranged from 10 days to 16 days [see Adverse Reactions ( 6.1 )] . Febrile neutropenia has been reported in <1% of patients receiving VERZENIO across trials. Two deaths due to neutropenic sepsis were observed in MONARCH 2. Inform patients to promptly report any episodes of fever to their healthcare provider [see Patient Counseling Information ( 17 )] . Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia [see Dosage and Administration ( 2.2 )] . 5.3 Interstitial Lung Disease (ILD) or Pneumonitis Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur in patients treated with VERZENIO and other CDK4/6 inhibitors. In VERZENIO-treated patients in early breast cancer (monarchE, N=2791), 3% of patients experienced ILD or pneumonitis of any grade: 0.4% were Grade 3 or 4 and there was one fatality (0.1%). In VERZENIO-treated patients in advanced or metastatic breast cancer (N=1108) (MONARCH 1, MONARCH 2, MONARCH 3, EMBER-3), 3.2% of VERZENIO-treated patients had ILD or pneumonitis of any grade: 0.5% had Grade 3 or 4, and 0.5% had fatal outcomes. Additional cases of ILD or pneumonitis have been observed in the postmarketing setting, with fatalities reported [see Adverse Reactions ( 6.2 )] . Monitor patients for pulmonary symptoms indicative of ILD or pneumonitis. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations. Withhold or reduce dose for patients who develop persistent or recurrent Grade 2 ILD or pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis [see Dosage and Administration ( 2.2 )] . 5.4 Hepatotoxicity Grade ≥3 ALT (2% to 6%) and AST (2% to 3%) were reported in patients receiving VERZENIO. Across four clinical trials in 3767 patients (monarchE, MONARCH 2, MONARCH 3, EMBER-3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87 days and the median time to resolution to Grade <3 was 13 to 14 days. The median time to onset of Grade ≥3 AST increases ranged from 71 to 185 days and the median time to resolution to Grade <3 ranged from 11 to 15 days. Monitor liver function tests (LFTs) prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or any Grade 3 or Grade 4 hepatic transaminase elevation [see Dosage and Administration ( 2.2 )] . 5.5 Venous Thromboembolism Across four clinical trials in 3767 patients (monarchE, MONARCH 2, MONARCH 3, EMBER-3), venous thromboembolic (VTE) events occurred in 2% to 5% of patients treated with VERZENIO. VTE events included deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, inferior vena cava thrombosis, jugular vein thrombosis, peripheral vein thrombosis and superficial vein thrombosis. In clinical trials, deaths due to VTE occurred in patients treated with VERZENIO. VERZENIO has not been studied in patients with early breast cancer who had a history of VTE. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate. Dose interruption is recommended for early breast cancer patients with any grade VTE event and for advanced or metastatic breast cancer patients with a Grade 3 or 4 VTE event [see Dosage and Administration ( 2.2 )] . 5.6 Embryo-Fetal Toxicity Based on findings from animal studies and the mechanism of action, VERZENIO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of abemaciclib to pregnant rats during the period of organogenesis caused teratogenicity and decreased fetal weight at maternal exposures that were similar to the human clinical exposure based on area under the curve (AUC) at the maximum recommended human dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with VERZENIO and for 3 weeks after the last dose [see Use in Specific Populations ( 8.1 , 8.3 ) and Clinical Pharmacology ( 12.1 )] . 5.7 Increased Serum Creatinine without Affecting Renal Function VERZENIO can increase serum creatinine. Across five clinical trials in 3899 patients (monarchE, MONARCH 1, MONARCH 2, MONARCH 3, and EMBER-3), increases in serum creatinine (mean increase, 0.2-0.3 mg/dL) occurred within the first 28-day cycle of VERZENIO treatment, remained elevated through the treatment, and were reversible upon treatment discontinuation. These increases were not associated with changes in glomerular function [see Adverse Reactions ( 6.1 )] . The increases in serum creatinine may be due to inhibition of renal tubular secretion transporters [see Clinical Pharmacology ( 12.3 )] . During VERZENIO treatment, use alternative measures that are not based on serum creatinine to assess renal function such as BUN, cystatin C, or calculated GFR.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Diarrhea [see Warnings and Precautions ( 5.1 )] . Neutropenia [see Warnings and Precautions ( 5.2 )] . Interstitial Lung Disease (ILD) or Pneumonitis [see Warnings and Precautions ( 5.3 )] . Hepatotoxicity [see Warnings and Precautions ( 5.4 )] . Venous Thromboembolism [see Warnings and Precautions ( 5.5 )] . Most common adverse reactions (incidence ≥20%) were diarrhea, infections, neutropenia, fatigue, abdominal pain, nausea, leukopenia, anemia, and vomiting. ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety population described in the Warnings and Precautions reflect exposure to VERZENIO in 3899 patients from five clinical trials including 132 patients treated with VERZENIO as monotherapy at 200 mg twice daily in MONARCH 1, 3767 patients treated with VERZENIO in combination with fulvestrant, tamoxifen, imlunestrant or an aromatase inhibitor at 150 mg twice daily in MONARCH 2, monarchE, EMBER-3, and MONARCH 3. The median duration of exposure ranged from 4.5 months in MONARCH 1 to 24 months in monarchE. The most common adverse reactions (incidence ≥20%) across clinical trials were: diarrhea, infections, neutropenia, fatigue, abdominal pain, nausea, leukopenia, anemia, and vomiting. Early Breast Cancer monarchE: VERZENIO in Combination with Tamoxifen or an Aromatase Inhibitor as Adjuvant Treatment Adult patients with HR-positive, HER2-negative, node-positive early breast cancer at a high risk of recurrence The safety of VERZENIO was evaluated in monarchE, a study of 5591 adult patients receiving VERZENIO in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) or endocrine therapy (tamoxifen or an aromatase inhibitor) alone [see Clinical Studies ( 14.1 )]. Patients were randomly assigned to receive 150 mg of VERZENIO orally, twice daily, in combination with tamoxifen or an aromatase inhibitor, or tamoxifen or an aromatase inhibitor, for two years or until discontinuation criteria were met. The median duration of VERZENIO treatment was 24 months (range: 1-28 months). Serious adverse reactions occurred in 15% of patients who received VERZENIO in combination with endocrine therapy (tamoxifen or an aromatase inhibitor). Serious adverse reactions in ≥1% of patients included venous thromboembolism (VTE) (1.2%) and pneumonia (1%). Fatal adverse reactions occurred in 0.8% of patients who received VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor), including: cardiac failure (0.1%), cardiac arrest, myocardial infarction, ventricular fibrillation, cerebral hemorrhage, cerebrovascular accident, pneumonitis, hypoxia, diarrhea, and mesenteric artery thrombosis (0.03% each). Permanent discontinuation of VERZENIO due to an adverse reaction occurred in 19% of patients. Adverse reactions which resulted in permanent discontinuation in >1% of patients were diarrhea (5%), and fatigue (2%). Dosage interruptions of VERZENIO due to an adverse reaction occurred in 62% of patients. Adverse reactions which required dosage interruptions in ≥5% of patients were diarrhea (20%), neutropenia (16%), leukopenia (7%), and fatigue (5%). Dose reductions of VERZENIO due to an adverse reaction occurred in 44% of patients. Adverse reactions which required dose reductions in ≥5% of patients were diarrhea (17%), neutropenia (8%), and fatigue (5%). The most common (>20%) adverse reactions, including laboratory abnormalities in the VERZENIO plus tamoxifen or an aromatase inhibitor arm and ≥2% higher than the tamoxifen or an aromatase inhibitor arm were: increased creatinine, decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, infections, fatigue, increased alanine aminotransferase (ALT), decreased platelets, increased aspartate aminotransferase (AST), nausea, and headache. Adverse reactions are shown in Table 8 and laboratory abnormalities are shown in Table 9 . Table 8: Adverse Reactions (≥10%) of Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE a Adverse reactions were graded using NCI CTCAE version 4.0 b Includes other related terms. Adverse Reaction a VERZENIO Plus Tamoxifen or an Aromatase Inhibitor N=2791 Tamoxifen or an Aromatase Inhibitor N=2800 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Gastrointestinal Disorders Diarrhea 84 8 0 9 0.2 0 Nausea 30 0.5 0 9 <0.1 0 Vomiting 18 0.5 0 4.6 0.1 0 Stomatitis b 14 0.1 0 5 0 0 Infections and Infestations Infections b 51 4.9 0.6 39 2.7 0.1 General Disorders and Administration Site Conditions Fatigue b 41 2.9 0 18 0.1 0 Nervous System Disorders Headache 20 0.3 0 15 0.2 0 Dizziness 11 0.1 0 7 <0.1 0 Metabolism and Nutrition Disorders Decreased appetite 12 0.6 0 2.4 <0.1 0 Skin and Subcutaneous Tissue Disorders Rash b 11 0.4 0 4.5 0 0 Alopecia 11 0 0 2.7 0 0 Clinically relevant adverse reactions in <10% of patients who received VERZENIO in combination with tamoxifen or an aromatase inhibitor in monarchE include: pruritus (9%), dyspepsia (8%), nail disorder (6%), increased lacrimation (6%), dysgeusia (5%), ILD/pneumonitis (3%), and VTE (3%). Table 9: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE VERZENIO Plus Tamoxifen or an Aromatase Inhibitor N=2791 Tamoxifen or an Aromatase Inhibitor N=2800 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Chemistry Creatinine increased 99 0.5 0 91 <0.1 0 ALT increased 37 2.5 <0.1 24 1.2 0 AST increased 31 1.5 <0.1 18 0.9 0 Potassium decreased 11 1.2 0.1 3.8 0.1 0.1 Hematology Neutrophils decreased 84 18 0.7 23 1.6 0.3 Hemoglobin decreased 68 1 0 17 0.1 0 Lymphocytes decreased 59 13 0.2 24 2.4 0.1 Platelets decreased 37 0.7 0.2 10 0.1 0.1 Advanced or Metastatic Breast Cancer MONARCH 3: VERZENIO in Combination with an Aromatase Inhibitor (Anastrozole or Letrozole) as Initial Endocrine-Based Therapy Postmenopausal Women with HR-positive, HER2-negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting The safety of VERZENIO was evaluated in MONARCH 3, a study of 488 women receiving VERZENIO in combination with an aromatase inhibitor or placebo in combination with an aromatase inhibitor [see Clinical Studies ( 14.2 )]. Patients were randomly assigned to receive 150 mg of VERZENIO or placebo orally twice daily, in combination with investigator's choice of anastrozole or letrozole once daily until discontinuation criteria were met. The median duration of VERZENIO treatment was 15.1 months (range: 5 days – 27.4 months). Serious adverse reactions occurred in 28% of patients who received VERZENIO plus an aromatase inhibitor. Serious adverse reactions in ≥1.5% of patients included infections (6%), VTE (2.5%) and diarrhea and anemia (1.5%, each). Fatal adverse reactions occurred in 3% of patients who received VERZENIO including underlying disease (0.9%), lung infection (0.9%), VTE (0.9%), pneumonitis (0.3%), and cerebral infarction (0.3%). Permanent discontinuation of VERZENIO due to an adverse reaction occurred in 13% of patients. Adverse reactions which resulted in permanent discontinuation in >1% of patients were diarrhea (2%), ALT increased (2%), infection (1%), and VTE (1%). Dosage interruptions of VERZENIO due to an adverse reaction occurred in 56% of patients. Adverse reactions which required dosage interruptions in ≥5% of patients were neutropenia (16%) and diarrhea (15%). Dose reductions of VERZENIO due to an adverse reaction occurred in 43% of patients. Adverse reactions which required dose reductions in ≥5% of patients were diarrhea (13%) and neutropenia (11%). The most common (≥20%) adverse reactions including laboratory abnormalities in the VERZENIO plus aromatase inhibitor arm and ≥2% higher than the placebo arm were: increased creatinine, decreased hemoglobin, diarrhea, decreased neutrophils, decreased lymphocytes, increased ALT, fatigue, infections, nausea, increased AST, decreased platelets, abdominal pain, anemia, vomiting, alopecia, and decreased appetite. Adverse reactions are shown in Table 10 and laboratory abnormalities in Table 11 . Table 10: Adverse Reactions (≥10%) in Patients Receiving VERZENIO Plus Anastrozole or Letrozole [with a Difference between Arms of ≥2%] in MONARCH 3 a Adverse reactions were graded using NCI CTCAE version 4.0 b Includes other related terms Adverse Reaction a VERZENIO plus Anastrozole or Letrozole N=327 Placebo plus Anastrozole or Letrozole N=161 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Gastrointestinal Disorders Diarrhea 81 9 0 30 1.2 0 Nausea 39 0.9 0 20 1.2 0 Abdominal pain 29 1.2 0 12 1.2 0 Vomiting 28 1.2 0 12 1.9 0 Constipation 16 0.6 0 12 0 0 Infections and Infestations Infections b 39 4 0.9 29 2.5 0.6 General Disorders and Administration Site Conditions Fatigue 40 1.8 0 32 0 0 Influenza like illness 10 0 0 8 0 0 Skin and Subcutaneous Tissue Disorders Alopecia 27 0 0 11 0 0 Rash 14 0.9 0 5 0 0 Pruritus 13 0 0 9 0 0 Metabolism and Nutrition Disorders Decreased appetite 24 1.2 0 9 0.6 0 Respiratory, Thoracic, and Mediastinal Disorders Cough 13 0 0 9 0 0 Dyspnea 12 0.6 0.3 6 0.6 0 Nervous System Disorders Dizziness 11 0.3 0 9 0 0 Investigations Decreased weight 10 0.6 0 3.1 0.6 0 Clinically relevant adverse reactions (<10%) in patients who received VERZENIO in combination with an aromatase inhibitor included: VTE (5%). Table 11: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Anastrozole or Letrozole [with a Difference Between Arms of ≥2%] in MONARCH 3 VERZENIO plus Anastrozole or Letrozole N=327 Placebo plus Anastrozole or Letrozole N=161 Laboratory Abnormality All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Chemistry Creatinine increased 98 2.2 0 84 0 0 ALT increased 48 6 0.6 25 1.9 0 AST increased 37 3.8 0 23 0.6 0 Hematology Hemoglobin decreased 82 1.6 0 28 0 0 Neutrophils decreased 80 19 2.9 21 2.6 0 Lymphocytes decreased 53 7 0.6 26 1.9 0 Platelets decreased 36 1.3 0.6 12 0.6 0 MONARCH 2: VERZENIO in Combination with Fulvestrant Women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression on or after prior adjuvant or metastatic endocrine therapy The safety of VERZENIO in combination with fulvestrant versus placebo was evaluated in 664 patients with HR-positive, HER2-negative advanced breast cancer in MONARCH 2 [see Clinical Studies ( 14.2 )] . Patients were randomized (2:1) to receive VERZENIO 150 mg orally twice daily in combination with fulvestrant (N=441) or placebo in combination with fulvestrant (N=223). Among patients treated with VERZENIO plus fulvestrant, the median duration of exposure was 12 months (range: 1 day – 27.8 months). Serious adverse reactions occurred in 22% of patients who received VERZENIO in combination with fulvestrant. Serious adverse reactions in >1% of patients included VTE and pneumonia (1.8%, each), diarrhea (1.6%), cough (1.4%), sepsis (1.4%) and nausea and acute kidney injury (1.1% each). Fatal adverse reactions occurred in 4% of patients who received VERZENIO plus fulvestrant including underlying disease (2%), sepsis (0.9%), pneumonitis and hepatotoxicity (0.5% each), and cerebral infarction (0.2%). Permanent discontinuation of VERZENIO due to an adverse reaction occurred in 9% of patients. Adverse reactions which resulted in permanent discontinuation in >1% of patients were infection (2%), and diarrhea and hepatotoxicity (1%, each). Dosage interruptions of VERZENIO due to an adverse reaction occurred in 52% of patients. Adverse reactions which required dosage interruptions in ≥5% of patients were diarrhea (19%) and neutropenia (16%). Dose reductions of VERZENIO due to an adverse reaction occurred in 43% of patients. Adverse reactions which required dose reductions in ≥5% of patients were diarrhea (19%) and neutropenia (10%). The most common (≥20%) adverse reactions, including laboratory abnormalities, in the VERZENIO plus fulvestrant arm and with a ≥ 2% higher than the placebo plus fulvestrant arm were: increased creatinine, decreased neutrophils, diarrhea, decreased hemoglobin, decreased platelets, fatigue, nausea, infections, increased ALT, increased AST, abdominal pain, decreased appetite, vomiting, and headache. Adverse reactions are shown in Table 12 and laboratory abnormalities in Table 13 . Table 12: Adverse Reactions (≥10%) in Patients Receiving VERZENIO Plus Fulvestrant [with a Difference Between Arms of ≥2%] in MONARCH 2 a Adverse reactions were graded using NCI CTCAE version 4.0 b Includes other related terms. Adverse Reaction a VERZENIO plus Fulvestrant N=441 Placebo plus Fulvestrant N=223 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Gastrointestinal Disorders Diarrhea 86 13 0 25 0.4 0 Nausea 45 2.7 0 23 0.9 0 Abdominal pain b 35 2.5 0 16 0.9 0 Vomiting 26 0.9 0 10 1.8 0 Stomatitis 15 0.5 0 10 0 0 General Disorders and Administration Site Conditions Fatigue b 46 2.7 0 32 0.4 0 Edema peripheral 12 0 0 7 0 0 Pyrexia 11 0.5 0.2 6 0.4 0 Infections and Infestations Infections b 43 5 0.7 25 3.1 0.4 Metabolism and Nutrition Disorders Decreased appetite 27 1.1 0 12 0.4 0 Nervous System Disorders Headache 20 0.7 0 15 0.4 0 Dysgeusia 18 0 0 2.7 0 0 Dizziness 12 0.7 0 6 0 0 Skin and Subcutaneous Tissue Disorders Alopecia 16 0 0 1.8 0 0 Pruritus 13 0 0 6 0 0 Rash 11 1.1 0 4.5 0 0 Respiratory, Thoracic and Mediastinal Disorders Cough 13 0 0 11 0 0 Investigations Weight decreased 10 0.2 0 2.2 0.4 0 Clinically relevant adverse reactions (<10%) in patients who received VERZENIO in combination with fulvestrant included: VTE (5%) Table 13: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Fulvestrant [with a Difference Between Arms of ≥2%]in MONARCH 2 VERZENIO plus Fulvestrant N=441 Placebo plus Fulvestrant N=223 All Grades % Grade 3 % Grade 4 % All Grades % Grade 3 % Grade 4 % Chemistry Creatinine increased 98 1.2 0 74 0 0 ALT increased 41 3.9 0.7 32 1.4 0 AST increased 37 3.9 0 25 3.7 0.5 Hematology Neutrophils decreased 87 29 3.5 30 3.7 0.5 Hemoglobin decreased 84 2.6 0 34 0.5 0 Lymphocytes decreased 63 12 0.2 32 1.8 0 Platelets decreased 53 0.9 1.2 15 0 0 EMBER-3: VERZENIO in Combination with Imlunestrant in Advanced or Metastatic Breast Cancer The safety of VERZENIO in combination with imlunestrant was evaluated in 535 patients with ER+, HER2- locally advanced or metastatic breast cancer previously treated with endocrine therapy with or without a prior CDK4/6 inhibitor in EMBER-3 [see Clinical Studies ( 14.2 )] . Patients received VERZENIO 150 mg orally twice daily in combination with imlunestrant 400 mg orally once daily (N=208), or imlunestrant monotherapy 400 mg, once daily (n=327). Among patients who were treated with VERZENIO in combination with imlunestrant, the median duration of exposure was 7.7 months (range 1 day to 25.3 months). Serious adverse reactions occurred in 21% of patients who received VERZENIO in combination with imlunestrant. Serious adverse reactions in >1% of patients included pneumonia (2.4%), abdominal pain, and renal failure (each 1.4%). Fatal adverse reactions occurred in 3.8% of patients who received VERZENIO in combination with imlunestrant, including pneumonia (1.4%), myocardial infarction, interstitial lung disease and sepsis (0.5%, each). Permanent discontinuation of VERZENIO due to an adverse reaction occurred in 3.4% of patients. Adverse reactions which resulted in permanent discontinuation of VERZENIO included: increased ALT (1.4%), bile duct stone, diarrhea, drug-induced liver injury, prolonged QT interval, fatigue, maculo-papular rash, renal failure, and vomiting (0.5% each). Dosage interruptions of VERZENIO due to an adverse reaction occurred in 59% of patients. Adverse reactions which required dosage interruptions of VERZENIO in ≥2% of patients included diarrhea (20%), neutropenia (10%), decreased neutrophils (8%), anemia (6%), nausea (6%), increased AST (2.4%), fatigue (2.4%), and vomiting (2.4%). Dose reductions of VERZENIO due to an adverse reaction occurred in 42% of patients. Adverse reactions which required dose reductions of VERZENIO in ≥1% of patients included: diarrhea (20%), neutropenia (5%), nausea (3.4%), decreased neutrophils (3.4%), fatigue (2.4%), anemia (1.9%), increased AST (1.9%), increased ALT (1.4%). The most common (≥10%) adverse reactions, including laboratory abnormalities were: decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, nausea, decreased platelets, fatigue, increased triglycerides, infections, increased AST, increased creatinine, increased ALT, vomiting, musculoskeletal pain, abdominal pain, decreased appetite, increased cholesterol, rash, cough, headache and decreased weight. Table 14 and 15 summarizes the adverse reactions and laboratory abnormalities, respectively, in EMBER-3. Table 14: Adverse Reactions (≥10%) in Patients Treated with VERZENIO in combination with Imlunestrant in EMBER-3 a Adverse reactions were graded using NCI CTCAE version 5.0. b Includes other related terms Adverse Reaction a VERZENIO plus Imlunestrant N=208 Imlunestrant N=327 All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Gastrointestinal Disorders Diarrhea 86 9 23 0.3 Nausea 51 1.9 18 0.3 Vomiting 32 0.5 10 0.6 Abdominal pain b 24 1.9 11 0.3 General Disorders and Administration Site Conditions Fatigue b 41 5 24 0.3 Infections and Infestations Infections b 36 7 25 3.4 Musculoskeletal Disorders Musculoskeletal pain b 25 1.4 31 2.8 Metabolism and Nutrition Disorders Decreased appetite b 22 1 9 0.3 Skin and Subcutaneous Tissue Disorders Rash b 14 1.4 4.9 0 Respiratory, Thoracic and Mediastinal Disorders Cough b 13 0 9 0 Nervous System Disorders Headache b 10 0.5 9 0 Investigations Decreased weight 10 0 4.6 0 Clinically relevant adverse reactions (<10%) in patients who received VERZENIO in combination with imlunestrant included: constipation (9%), stomatitis (9%), fever (9%), urinary tract infection (8%), dizziness (8%), hot flush (6%), insomnia (6%), arrhythmia (6%), alopecia (5%), back pain (4.8%), venous thromboembolic event (4.8%) and interstitial lung disease or pneumonitis (2.9%). Table 15: Lab Abnormalities (≥10%) in Patients Treated with VERZENIO in Combination with Imlunestrant in EMBER-3 a Graded according to NCI CTCAE version 5. b The denominator used to calculate the frequency varied from 178 to 205 based on the number of patients with a baseline value and at least one post-treatment value. Lab Abnormality a VERZENIO plus Imlunestrant b Imlunestrant b All Grades % Grades 3 or 4 % All Grades % Grades 3 or 4 % Hematology Neutrophils decreased 86 21 28 4.3 Hemoglobin decreased 81 9 34 2.2 Lymphocytes decreased 58 9 29 2.2 Platelets count decreased 48 2.4 18 2.8 Chemistry Triglycerides increased 40 2.3 22 0 AST increased 36 2.5 27 1.9 Creatinine increased 36 1.1 6 0.3 ALT increased 33 5 22 1.3 Cholesterol increased 18 0 12 0.4 MONARCH 1: VERZENIO Administered as a Monotherapy in Metastatic Breast Cancer Patients with HR-positive, HER2-negative breast cancer who received prior endocrine therapy and 1-2 chemotherapy regimens in the metastatic setting The safety of VERZENIO was evaluated in 132 women with HR-positive, HER2-negative metastatic breast cancer whose disease progressed during or after endocrine therapy, had received a taxane in any setting, and who had received 1 or 2 prior chemotherapy regimens in the metastatic setting [see Clinical Studies ( 14.2 )]. Patients received VERZENIO 200 mg orally twice daily. The median duration of exposure to VERZENIO was 4.5 months (range: 8 days – 20.4 months). Serious adverse reactions occurred in 24% of patients who received VERZENIO. Serious adverse reactions in >2% of patients included infections (4.5%), increased creatinine (3%), dehydration, nausea, and abdominal pain (2.3%, each). Fatal adverse reactions occurred in 2.3% of patients who received VERZENIO including infection (1.5%) and pneumonitis (0.8%). Permanent discontinuation of VERZENIO due to adverse reactions occurred in 8% of patients. Adverse reactions which resulted in permanent discontinuation of VERZENIO included abdominal pain, arterial thrombosis, increased AST, increased creatinine, chronic kidney disease, diarrhea, prolonged QT interval, fatigue, hip fracture, and lymphopenia (0.8% each). Dosage interruptions of VERZENIO due to an adverse reaction occurred in 58% of patients. Adverse reactions which required dosage interruptions in ≥5% of patients were diarrhea (24%), neutropenia (16%), fatigue (10%), vomiting (6%), and nausea (5%). Dose reductions of VERZENIO due to an adverse reaction occurred in 49% of patients. Adverse reactions which resulted in dose reductions in ≥5% of patients were diarrhea (20%), neutropenia (11%), and fatigue (9%). The most common (≥20%) adverse reactions, including laboratory abnormalities, in patients treated with VERZENIO were: increased creatinine, diarrhea, decreased hemoglobin, fatigue, nausea, decreased appetite, decreased lymphocytes, decreased platelets, abdominal pain, vomiting, infections, increased ALT, increased AST and headache. Adverse reactions are shown in Table 16 and laboratory abnormalities in Table 17 . Table 16: Adverse Reactions (≥10%) of Patients in MONARCH 1 a Adverse reactions were graded using NCI CTCAE version 4.0 b Includes other related terms Adverse Reaction a VERZENIO N=132 All Grades % Grade 3 % Grade 4 % Gastrointestinal Disorders Diarrhea 90 20 0 Nausea 64 4.5 0 Abdominal pain 39 2.3 0 Vomiting 35 1.5 0 Constipation 17 0.8 0 Dry mouth 14 0 0 Stomatitis 14 0 0 General Disorders and Administration Site Conditions Fatigue b 65 13 0 Pyrexia 11 0 0 Metabolism and Nutrition Disorders Decreased appetite 45 3.0 0 Dehydration 10 2.3 0 Infections and Infestations Infections 31 4.5 0 Nervous System Disorders Headache 20 0 0 Dysgeusia 12 0 0 Dizziness 11 0 0 Respiratory, Thoracic and Mediastinal Disorders Cough 19 0 0 Musculoskeletal and Connective Tissue Disorders Arthralgia 15 0 0 Investigations Weight decreased 14 0 0 Skin and Subcutaneous Tissue Disorders Alopecia 12 0 0 Table 17: Laboratory Abnormalities for Patients Receiving VERZENIO in MONARCH 1 VERZENIO N=132 All Grades % Grade 3 % Grade 4 % Chemistry Creatinine increased 99 0.8 0 ALT increased 31 3.1 0 AST increased 30 3.8 0 Hematology Neutrophils decreased 88 22 4.6 Hemoglobin decreased 69 0 0 Lymphocytes decreased 42 13 0.8 Platelets decreased 41 2.3 0 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of VERZENIO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Respiratory disorders : Interstitial lung disease (ILD)/pneumonitis [see Warnings and Precautions ( 5.3 )] .
adverse reactions table
<table ID="t8" width="100%"> <caption>Table 8: Adverse Reactions (≥10%) of Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE </caption> <col width="25.000%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <tfoot> <tr> <td colspan="7" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>a</sup> Adverse reactions were graded using NCI CTCAE version 4.0 </paragraph> </td> </tr> <tr> <td colspan="7" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>b</sup> Includes other related terms. </paragraph> </td> </tr> </tfoot> <tbody> <tr> <td rowspan="2" align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> <content styleCode="bold">Adverse Reaction</content> <content styleCode="bold"> <sup>a</sup> </content> </td> <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">VERZENIO Plus</content> <content styleCode="bold">Tamoxifen or an Aromatase Inhibitor</content> <content styleCode="bold">N=2791</content> </td> <td colspan="3" align="center" valign="bottom" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Tamoxifen or an Aromatase Inhibitor</content> <content styleCode="bold">N=2800</content> </td> </tr> <tr> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 3</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 4</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 3</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 4</content> <content styleCode="bold">%</content> </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Gastrointestinal Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Diarrhea </td> <td align="center" valign="top" styleCode="Botrule Rrule">84 </td> <td align="center" valign="top" styleCode="Botrule Rrule">8 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Nausea </td> <td align="center" valign="top" styleCode="Botrule Rrule">30 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.5 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">9 </td> <td align="center" valign="top" styleCode="Botrule Rrule"><0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Vomiting </td> <td align="center" valign="top" styleCode="Botrule Rrule">18 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.5 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">4.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Stomatitis<sup>b</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">14 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">5 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Infections and Infestations</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Infections<sup>b</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">51 </td> <td align="center" valign="top" styleCode="Botrule Rrule">4.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">39 </td> <td align="center" valign="top" styleCode="Botrule Rrule">2.7 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">General Disorders and Administration Site Conditions</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Fatigue<sup>b</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">41 </td> <td align="center" valign="top" styleCode="Botrule Rrule">2.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">18 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Nervous System Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Headache </td> <td align="center" valign="top" styleCode="Botrule Rrule">20 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">15 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Dizziness </td> <td align="center" valign="top" styleCode="Botrule Rrule">11 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">7 </td> <td align="center" valign="top" styleCode="Botrule Rrule"><0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Metabolism and Nutrition Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Decreased appetite </td> <td align="center" valign="top" styleCode="Botrule Rrule">12 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">2.4 </td> <td align="center" valign="top" styleCode="Botrule Rrule"><0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Rash<sup>b</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">11 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.4 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">4.5 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Alopecia </td> <td align="center" valign="top" styleCode="Botrule Rrule">11 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">2.7 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> </tbody> </table>
adverse reactions table
<table ID="t9" width="100%"> <caption>Table 9: Laboratory Abnormalities (≥10%) in Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of ≥2%] in monarchE </caption> <col width="25.000%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <tbody> <tr> <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/> <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">VERZENIO</content> <content styleCode="bold">Plus Tamoxifen or an Aromatase Inhibitor</content> <content styleCode="bold">N=2791</content> </td> <td colspan="3" align="center" valign="bottom" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Tamoxifen or an Aromatase Inhibitor</content> <content styleCode="bold">N=2800</content> </td> </tr> <tr> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 3</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 4</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 3</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 4</content> <content styleCode="bold">%</content> </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Chemistry</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Creatinine increased </td> <td align="center" valign="top" styleCode="Botrule Rrule">99 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.5 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">91 </td> <td align="center" valign="top" styleCode="Botrule Rrule"><0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">ALT increased </td> <td align="center" valign="top" styleCode="Botrule Rrule">37 </td> <td align="center" valign="top" styleCode="Botrule Rrule">2.5 </td> <td align="center" valign="top" styleCode="Botrule Rrule"><0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">24 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">AST increased </td> <td align="center" valign="top" styleCode="Botrule Rrule">31 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.5 </td> <td align="center" valign="top" styleCode="Botrule Rrule"><0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">18 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Potassium decreased </td> <td align="center" valign="top" styleCode="Botrule Rrule">11 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">3.8 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Hematology</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Neutrophils decreased </td> <td align="center" valign="top" styleCode="Botrule Rrule">84 </td> <td align="center" valign="top" styleCode="Botrule Rrule">18 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.7 </td> <td align="center" valign="top" styleCode="Botrule Rrule">23 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hemoglobin decreased </td> <td align="center" valign="top" styleCode="Botrule Rrule">68 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">17 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Lymphocytes decreased </td> <td align="center" valign="top" styleCode="Botrule Rrule">59 </td> <td align="center" valign="top" styleCode="Botrule Rrule">13 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">24 </td> <td align="center" valign="top" styleCode="Botrule Rrule">2.4 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Platelets decreased </td> <td align="center" valign="top" styleCode="Botrule Rrule">37 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.7 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">10 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.1 </td> </tr> </tbody> </table>
adverse reactions table
<table ID="t10" width="100%"> <caption>Table 10: Adverse Reactions (≥10%) in Patients Receiving VERZENIO Plus Anastrozole or Letrozole [with a Difference between Arms of ≥2%] in MONARCH 3 </caption> <col width="25.000%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <col width="12.500%" align="left"/> <tfoot> <tr> <td colspan="7" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>a</sup> Adverse reactions were graded using NCI CTCAE version 4.0 </paragraph> </td> </tr> <tr> <td colspan="7" align="left" valign="top"> <paragraph styleCode="footnote"> <sup>b</sup> Includes other related terms </paragraph> </td> </tr> </tfoot> <tbody> <tr> <td rowspan="2" align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> <content styleCode="bold">Adverse Reaction</content> <content styleCode="bold"> <sup>a</sup> </content> </td> <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">VERZENIO plus</content> <content styleCode="bold">Anastrozole or Letrozole</content> <content styleCode="bold">N=327</content> </td> <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Rrule"> <content styleCode="bold">Placebo plus</content> <content styleCode="bold">Anastrozole or Letrozole</content> <content styleCode="bold">N=161</content> </td> </tr> <tr> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 3</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 4</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">All Grades</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 3</content> <content styleCode="bold">%</content> </td> <td align="center" valign="top" styleCode="Botrule Rrule"> <content styleCode="bold">Grade 4</content> <content styleCode="bold">%</content> </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Gastrointestinal Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Diarrhea </td> <td align="center" valign="top" styleCode="Botrule Rrule">81 </td> <td align="center" valign="top" styleCode="Botrule Rrule">9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">30 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Nausea </td> <td align="center" valign="top" styleCode="Botrule Rrule">39 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">20 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Abdominal pain </td> <td align="center" valign="top" styleCode="Botrule Rrule">29 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">12 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Vomiting </td> <td align="center" valign="top" styleCode="Botrule Rrule">28 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">12 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Constipation </td> <td align="center" valign="top" styleCode="Botrule Rrule">16 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">12 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Infections and Infestations</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Infections<sup>b</sup> </td> <td align="center" valign="top" styleCode="Botrule Rrule">39 </td> <td align="center" valign="top" styleCode="Botrule Rrule">4 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">29 </td> <td align="center" valign="top" styleCode="Botrule Rrule">2.5 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">General Disorders and Administration Site Conditions</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Fatigue </td> <td align="center" valign="top" styleCode="Botrule Rrule">40 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.8 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">32 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Influenza like illness </td> <td align="center" valign="top" styleCode="Botrule Rrule">10 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">8 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Alopecia </td> <td align="center" valign="top" styleCode="Botrule Rrule">27 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">11 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Rash </td> <td align="center" valign="top" styleCode="Botrule Rrule">14 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">5 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Pruritus </td> <td align="center" valign="top" styleCode="Botrule Rrule">13 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Metabolism and Nutrition Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Decreased appetite </td> <td align="center" valign="top" styleCode="Botrule Rrule">24 </td> <td align="center" valign="top" styleCode="Botrule Rrule">1.2 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Respiratory, Thoracic, and Mediastinal Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Cough </td> <td align="center" valign="top" styleCode="Botrule Rrule">13 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Dyspnea </td> <td align="center" valign="top" styleCode="Botrule Rrule">12 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3 </td> <td align="center" valign="top" styleCode="Botrule Rrule">6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Nervous System Disorders</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Dizziness </td> <td align="center" valign="top" styleCode="Botrule Rrule">11 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.3 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">9 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> <tr> <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule"> <content styleCode="bold">Investigations</content> </td> </tr> <tr> <td align="left" valign="top" styleCode="Botrule Lrule Rrule"> Decreased weight </td> <td align="center" valign="top" styleCode="Botrule Rrule">10 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> <td align="center" valign="top" styleCode="Botrule Rrule">3.1 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0.6 </td> <td align="center" valign="top" styleCode="Botrule Rrule">0 </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.